Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma

References

• Friedmann AM, Wolfson JA, Hudson MM, et al. Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy. Pediatr Blood Cancer. 2013;60(9):1458–1463.
   PubMed Web of Science ®Google Scholar
• Lundgaard AY, Hjalgrim LL, Berthelsen AK, et al. PW VI-X-01 relapse-localization in pediatric patients with Hodgkin lymphoma. Klinische Pädiatrie. 2020;232(02):PW–VI.
   Google Scholar
• Kelly KM. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood. 2015;126(22):2452–2458.
   PubMed Web of Science ®Google Scholar
• Shankar A, Hayward J, Kirkwood A, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma–results of the UK HD 3 relapse treatment strategy. Br J Haematol. 2014;165(4):534–544.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–623.
   PubMed Web of Science ®Google Scholar
• Martin A, Fernández‐Jiménez MC, Caballero MD, et al. Long‐term follow‐up in patients treated with Mini‐BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001;113(1):161–171.
   PubMed Web of Science ®Google Scholar
• Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol. 2017;8(10):293–302.
   PubMed Web of Science ®Google Scholar
• Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol. 2011;152(3):249–260.
   PubMed Web of Science ®Google Scholar
• Hsu SC, Metzger ML, Hudson MM, et al. Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil. Pediatr Blood Cancer. 2007;49(2):139–144.
   PubMed Web of Science ®Google Scholar
• Molyneux E, Scanlan T, Chagaluka G, et al. Haematological cancers in African children: progress and challenges. Br J Haematol. 2017;177(6):971–978.
   PubMed Web of Science ®Google Scholar
• White Y, Castle VP, Haig A. Pediatric oncology in developing countries: challenges and solutions. J Pediatr. 2013;162(6):1090–1091.
   PubMed Web of Science ®Google Scholar
• Gelband H, Sloan FA, editors. Cancer control opportunities in low-and middle-income countries. Washington, DC: National Academies Press; 2007.
   Google Scholar
• Horton S, Gauvreau CL. Cancer in low-and middle-income countries: an economic overview. Cancer. 2015;3:263–280.
   Google Scholar
• Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Cin Oncol. 2009;27(9):1456–1461.
   PubMed Web of Science ®Google Scholar
• Beaty RS, Bernhardt MB, Berger AH, et al. Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: quality and cost implications. Pediatr Blood Cancer. 2015;62(11):1925–1928.
   PubMed Web of Science ®Google Scholar
• Getz KD, Li Y, Szymczak JE, et al. Home or away from home: a multi-institution study comparing medical outcomes, patient perspectives, and health-related quality of life for outpatient versus inpatient management after chemotherapy for pediatric acute myeloid leukemia. Mov Ecol. 2019;134(Supplement_1):379–379.
   Google Scholar
• Collins JJ, Devine TD, Dick GS, et al. The measurement of symptoms in young children with cancer: the validation of the Memorial Symptom Assessment Scale in children aged 7–12. J Pain Symptom Manage. 2002;23(1):10–16.
   PubMed Web of Science ®Google Scholar
• Körholz D, Wallace WH, EuroNet Pediatric Hodgkin's Lymphoma Group. First international Inter-Group Study for classical Hodgkin's Lymphoma in Children and Adolescents. EuroNet-PHL-C1. Radiotherapy Manual. 2006:86–87.
   Google Scholar
• Daw S, Hasenclever D, Mascarin M, et al. Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. HemaSphere. 2020;4(1):e329.
   PubMed Web of Science ®Google Scholar
• Stoneham S, Ashley S, Pinkerton CR, United Kingdom Children's Cancer Study Group, et al. United Kingdom Children's Cancer Study Group. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol. 2004;26(11):740–745.
   PubMed Web of Science ®Google Scholar
• Wali R, Saeed H, Patrus N, et al. Outcomes of refractory and relapsed Hodgkin lymphoma with autologous stem-cell transplantation: a single institution experience. J Glob Oncol. 2019;5:1–6.
   PubMed Web of Science ®Google Scholar
• Marr K, Ronsley R, Nadel H, et al. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2020;67(4):e28167.
   PubMed Web of Science ®Google Scholar
• Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41.
   PubMed Web of Science ®Google Scholar
• Russo A, Pulsoni A, Viviani S, et al. Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) is an effective regimen for heavily pretreated, relapsed/refractory Hodgkin lymphoma patients: a multicenter, retrospective real-world study. Blood. 2018;132(Supplement 1):1655–1655.
   Google Scholar
• Sherrod AM, Brufsky A, Puhalla S. A case of late-onset gemcitabine lung toxicity. Clin Med Insights Oncol. 2011;5:CMO.S6643.
   Google Scholar
• Gardini AC, Aquilina M, Oboldi D, et al. Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer. 2013;13(1):542.
   PubMedGoogle Scholar
• Pulkkanen K, Kataja V, Johansson R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother. 2003;15(3):287–289.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Ronckers CM. Anthracyclines and alkylating agents: new risk factors for breast cancer in childhood cancer survivors. J Clin Oncol. 2016;34(9):891–894.
   PubMed Web of Science ®Google Scholar
• Turcotte LM, Liu Q, Yasui Y, et al. Chemotherapy and risk of subsequent malignant neoplasms in the Childhood Cancer Survivor Study cohort. J Cin Oncol. 2019;37(34):3310–3319.
   PubMedGoogle Scholar